Synthesis and In-Vitro Antimycobacterial Evaluation of 4-Arylidene-2-Phenyl-6-(Aryl)-4,5-Dihydropyridazin-3(2H)-One Derivatives

被引:1
作者
Almehmadi, Mazen M. [1 ]
Alsaiari, Ahad Amer [2 ]
Asif, Mohammad [3 ]
机构
[1] Taif Univ, Coll Appl Med Sci, Dept Clin Lab Sci, POB 11099, Taif 21944, Saudi Arabia
[2] Jazan Univ, Coll Appl Med Sci, Dept Med Lab Technol, Jazan, Saudi Arabia
[3] Glocal Univ, Glocal Sch Pharm, Saharanpur 247121, Uttar Pradesh, India
关键词
pyridazinone; antimycobacterial activity; Mycobacterium tuberculosis; synthesis; heterocyclic compounds; drug resistance; spectral data; PYRIDAZINONE DERIVATIVES; ANTITUBERCULAR ACTIVITY; BIOLOGICAL EVALUATION; DESIGN; DRUGS; VASORELAXANT; ANALOGS;
D O I
10.1007/s11094-023-02876-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 4-arylidene-2-phenyl-6-(aryl)-4,5-dihydropyridazin-3(2H)-one derivatives (3a-3g and 3a'-3g') have been synthesized and evaluated as antimycobacterial agents by microplate alamar blue assay (MABA) method. Title compounds 3a-3g and 3a'-3g' were synthesized by reaction of 6-aryl-2-phenyl-4,5-dihydropyridazin-3(2H)-one (2a, 2b) with various aromatic aldehydes. Compounds 2a and 2b were synthesized from 4-aryl-4-oxobutanoic acids (1a,1b) by reaction ofphenyl hydrazine with appropriate aromatic compounds and succinic anhydride. The structures of synthesized compounds have been established by IR, H-1 NMR, and mass spectroscopy and elemental analysis. All synthesized compounds (3a-3g and 3a'-3g') exhibited significant antimycobacterial activity. Compound 3g showed maximum activity and compounds 3b, 3b', 3e, 3e', 3g'showed moderate activity as compared to the reference drugsisoniazid (MIC 3.125 mu g/mL) and streptomycin (MIC 6.25 mu g/mL).
引用
收藏
页码:265 / 273
页数:9
相关论文
共 54 条
  • [1] Pyridazinone derivatives: Design, synthesis, and in vitro vasorelaxant activity
    Abouzid, Khaled
    Hakeem, Maha Abdel
    Khalil, Ornnya
    Maklad, Yosria
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (01) : 382 - 389
  • [2] The therapeutic journey of pyridazinone
    Akhtar, Wasim
    Shaquiquzzaman, M.
    Akhter, Mymoona
    Verma, Garima
    Khan, Mohemmed Faraz
    Alam, M. Mumtaz
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 123 : 256 - 281
  • [3] Asif M., 2011, Glob. J. Pharmacol, V5, P18, DOI [10.1111/j.2042-7158.1953.tb13950.x, DOI 10.1111/J.2042-7158.1953.TB13950.X]
  • [4] Asif M., 2013, IRAN J PHARM RES, V9, P67
  • [5] Asif M., 2011, J SCI RES, V9, P481
  • [6] Asif M, 2014, SOP T ORG CHEM, V1, P1, DOI [10.15764/STAC.2014.01001, DOI 10.15764/STAC.2014.01001]
  • [7] Asif M., 2010, Int. J. ChemTech Res, V2, P1112
  • [8] Asif M., 2014, Int. J. Adv. Chem, V2, P148, DOI [10.14419/ijac.v2i2.2661, DOI 10.14419/IJAC.V2I2.2661]
  • [9] Studies on new substituted pyridazinones: synthesis and biological evaluation
    Asif, Nloliaiiimad
    Singh, Anita
    Khan, Shah Alam
    Husain, Asif
    [J]. BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 54 (03)
  • [10] Bastian I., 2000, MULTIDRUG RESISTANT, P79, DOI [10.1007/978-94-011-4084-3, DOI 10.1007/978-94-011-4084-3]